Abstract

The sequential functionalization of graphene (Gr) with oleylamine (ODA) and diethanolamine (DEA) was performed to produce amphiphilic Janus-type graphene nanosheets (DEA-f-Gr-f-ODA). The Janus graphene was self-assembled in 3D superstructures with hydrophilic external surface and hydrophobic internal space. The DEA-f-Gr-f-ODA nanoparticles were investigated as platforms for the hydrophobic anticancer drug camptothecin (CPT). The colloidal stability, drug loading and drug release properties of the DEA-f-Gr-f-ODA nanoparticles were determined. The viability of A549 cancer cells in the presence of increasing concentrations of free CPT and blank and drug-loaded DEA-f-Gr-f-ODA nanoparticles was assessed with MTT accompanied with PI/Annexin-V apoptosis assessment with flow cytometry. The uptake of DEA-f-Gr-f-ODA nanoparticles by the A549 cells was also evaluated with flow cytometry. The hemocompatibility of DEA-f-Gr-f-ODA nanoparticles was assessed with a hemolysis assay. The Janus graphene nanoparticles could host an exceptionally large amount of CPT, achieving more than double CPT loading compared to graphene-based CPT platforms reported so far, and released it in a slow biphasic fashion. The cytotoxicity and hemolysis assays provided evidence for the biocompatibility of the DEA-f-Gr-f-ODA nanoparticles and the CPT-loaded DEA-f-Gr-f-ODA nanoparticles were more cytotoxic against a human cancer cell line than free CPT, inducing a higher degree of apoptosis to the cancer cells.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.